Efficacy of Sharapunkhadi yoga and life style modification in the management of Non Alcoholic Fatty Liver Disease

A Randomized placebo controlled pharmaco-clinical study of Sharapunkhadi Yoga and lifestyle modification in the management of Non Alcoholic Fatty Liver Disease - NAFLD ( Non Alcoholic Fatty Liver Disease)

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2016/02/006623

Enrollment

Registered

2016-02-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K760- Fatty (change of) liver, not elsewhere classified Health Condition 2: null- USG findings suggestive of NAFLD Grade I, II & III

Interventions

Intervention1: A Randomized placebo controlled pharmaco-clinical study of Sharapunkhadi Yoga and Lifestyle modification in the management of Non-Alcoholic Fatty Liver Disease: Assess the efficacy of S

Eligibility

Inclusion criteria

Inclusion criteria: Patients of either sex of age group above 25 yrs and below 60yrs USG findings suggestive of Non Alcoholic Fatty Liver Disease grade I II III Both freshly detected and previously diagnosed cases of NAFLD

Exclusion criteria

Exclusion criteria: Patient aged below 25 years and above 60 years pregnant ladies Patients with uncontrolled diabetes or hypertension Patients with complications of Metabolic syndrome like Cerebrovascular accident Myocardial Infarction Chronic Kidney disease Patients consuming hepatotoxic medicines alcohol or other narcotic substances Patients suffering from Cirrhosis Ascites variceal haemorrhage coagulopathy hepato renal syndrome Patients having history of viral hepatitis auto immune liver diseases like Primary biliary cirrhosis primary sclerosing cholangitis autoimmune hepatitis metabolic disorders like Wilsons disease haemochromatosis Patients suffering from HIV TB other infectious diseases malignancies major psychiatric problems or any other serious illnesses

Design outcomes

Primary

Measure	Time frame
It is expected that the trial drug will normalize Liver Function tests and reverse fatty changes of liverTimepoint: 8 weeks	—

Secondary

Measure	Time frame
By providing better effect on Non Alcoholic Fatty Liver Disease drug may reduce the risk of Non Alcoholic Steato Hepatitis Fibrosis Cirrhosis Ascites and further complications of end stage liver disease and thus improve quality of life.Timepoint: 8 weeks treatment and 4 weeks follow up	—

Countries

India

Contacts

Public ContactREMYA E

I P G T and R A JAMNAGAR

mandipgoyal22@gmail.com9427572306

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026